Value Line investment survey


Also found in: Acronyms.

Value Line investment survey

A proprietary service that ranks stocks for timeliness and safety.

The Value Line Investment Survey

A research survey on hundreds of stocks conducted by Value Line Inc. The Value Line Investment Survey uses financial data and other information to attempt to predict future performance for stocks representing the vast majority of American market capitalization. The Survey is available by subscription and is updated regularly.
References in periodicals archive ?
Partners were required to present their ideas for investments using the Stock Selection Guide and the Value Line Investment Survey, publications printed by the National Association of Investors Inc.
You can get a solid overview of a company's financial health by using the annual report together with resources such as Standard & Poor's Stock Reports and Value Line Investment Survey. You'll learn about the company's current standing as well as its future prospects.
Financial newsletters and publications that will become required reading include: Value Line Investment Survey (800-833-0046) a weekly newsletter that evaluates some 1,700 companies, Morningstar Mutual Funds (312-697-4305), a biweekly newsletter that rates over 1,300 mutual funds and The Moneypaper (914-381-5400), a monthly newsletter that covers the dividend reinvestment plans of more than 400 companies.
Industrial Outlook, which profiles trade forecast and import-export patterns of 350 countries; Value Line Investment Surveys, Parts 2 & 3, which offer overviews of 91 industry groups in addition to analyses of industries, companies, and financial market; and Standard & Poor's Industry Surveys, which feature forecast covering 21 industries as well as marketing and investment analysis.
Also, Value Line Investment Surveys [1983] reported that the price of Tylenol had not returned to its premium level over the prices of other pain relievers.
According to Value Line Investment Surveys [1982], the estimated annual profits for the Tylenol line for 1982 were $80 million.
According to Value Line Investment Surveys [1982], Johnson & Johnson was also supposed to have stretched out its lead in the drug market by means of the introduction of a dozen or more new drugs by the mid-1980s.
Morningstar and Value Line investment surveys (available in your local library) list an approximated statistic for this value, which can also be found in annual and semiannual reports from the funds themselves.